🩸 Alzheimer's Prevention Trial Biomarker Enrollment Simulator

Asymptomatic Biomarker-Positive Population

Preclinical Alzheimer's biomarker-positive adults form the trial's target pool, placeholder.

• 60–80 yrs: Target age range (Placeholder eligibility range)
• Normal / unimpaired: Cognitive status (Placeholder inclusion note)
• ~20–30%: Biomarker prevalence (Placeholder population estimate)
• Registries & cohorts: Recruitment source (Placeholder sourcing note)

Defining the preclinical target population

Placeholder: rationale for enrolling asymptomatic biomarker-positive adults.

Blood Biomarker Pre-Screening Funnel

A blood-based assay filters the population before costlier confirmatory testing, placeholder.

• Plasma p-tau / Aβ: Assay type (Placeholder assay note)
• ~20%: Pre-screen positivity (Placeholder rate estimate)
• Low relative to PET: Cost per test (Placeholder cost note)
• Days: Turnaround (Placeholder turnaround estimate)

Blood test as a funnel narrowing step

Placeholder: blood biomarker pre-screening reduces need for confirmatory scans.

Confirmatory PET/CSF Testing

Amyloid PET or CSF testing confirms pre-screen-positive candidates, placeholder.

• PET or CSF: Confirmation method (Placeholder method note)
• ~60–70%: Confirmatory positivity (Placeholder concordance figure)
• High relative to blood test: Cost (Placeholder cost note)
• Moderate–high: Participant burden (Placeholder burden note)

Confirmatory testing accuracy and burden

Placeholder: PET/CSF confirmatory step and its accuracy trade-offs.

Trial Enrollment Eligibility Criteria

Confirmed-positive candidates are checked against remaining eligibility criteria, placeholder.

• Normal range scores: Cognitive criteria (Placeholder criteria note)
• Defined exclusions: Comorbidity limits (Placeholder exclusion note)
• Informed consent: Consent process (Placeholder consent note)
• ~1 in 15 screened: Final enroll rate (Placeholder funnel figure)

Final eligibility gate before randomization

Placeholder: eligibility criteria applied before final randomization.

Prevention Trial Cognitive Endpoint Tracking

Enrolled participants are followed on cognitive and biomarker endpoints, placeholder.

• Cognitive composite: Primary endpoint (Placeholder endpoint note)
• Multi-year: Follow-up duration (Placeholder duration estimate)
• Biomarker trajectories: Secondary endpoints (Placeholder secondary note)
• Periodic assessments: Visit cadence (Placeholder cadence note)

Tracking cognitive trajectories over time

Placeholder: long-term cognitive endpoint tracking design in prevention trials.

Placeholder key insight: early biomarker enrollment enables prevention-focused endpoints.